

Angelo Vacca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4582325/publications.pdf>

Version: 2024-02-01

509
papers

22,336
citations

10650

74
h-index

21843

118
g-index

516
all docs

516
docs citations

516
times ranked

23868
citing authors

#	ARTICLE	IF	CITATIONS
1	The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. <i>Clinical and Experimental Medicine</i> , 2023, 23, 255-272.	1.9	11
2	Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. <i>Clinical and Experimental Medicine</i> , 2022, 22, 65-74.	1.9	41
3	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
4	Inborn Error of Immunity: A Journey Through Novel Genes and Clinical Presentation. , 2022, , 798-818.		2
5	Right atrium enlargement is related to increased heart damage and mortality in well-controlled hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 420-428.	1.1	5
6	Highlights in clinical medicine—Giant cell arteritis, polymyalgia rheumatica and Takayasu’s arteritis: pathogenic links and therapeutic implications. <i>Clinical and Experimental Medicine</i> , 2022, 22, 509-518.	1.9	1
7	Antiangiogenic drugs as chemosensitizers in hematological tumors. , 2022, , 111-125.		0
8	Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs. <i>Journal of Pathology</i> , 2022, 256, 402-413.	2.1	15
9	Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection. <i>Pathogens and Global Health</i> , 2022, 116, 297-304.	1.0	7
10	The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet). <i>Journal of Clinical Immunology</i> , 2022, 42, 935-946.	2.0	21
11	The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”; Clinical Perspectives and Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1963.	1.7	9
12	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. <i>Journal of Clinical Medicine</i> , 2022, 11, 2513.	1.0	15
13	Follicular helper T cell signature of replicative exhaustion, apoptosis, and senescence in common variable immunodeficiency. <i>European Journal of Immunology</i> , 2022, 52, 1171-1189.	1.6	9
14	P87—MEDIASTINAL SYNDROME REVEALED HEART LOCALIZATION OF A PRIMARY MEDIASTINAL “CELL LYMPHOMA. <i>European Heart Journal Supplements</i> , 2022, 24, .	0.0	0
15	P365—CARDIOVASCULAR RISK SCORE MAY BE USEFUL IN STRATIFY DEATH RISK IN HOSPITALIZED COVID19 PATIENTS. <i>European Heart Journal Supplements</i> , 2022, 24, .	0.0	0
16	A Challenging Case of Visceral Leishmaniasis. <i>Reports</i> , 2022, 5, 23.	0.2	3
17	Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7302.	1.8	0
18	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. <i>Haematologica</i> , 2021, 106, 1943-1956.	1.7	46

#	ARTICLE	IF	CITATIONS
19	Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers?. <i>Surgery</i> , 2021, 169, 27-33.	1.0	10
20	TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. <i>Leukemia and Lymphoma</i> , 2021, 62, 337-347.	0.6	2
21	Takayasu arteritis: a cohort of Italian patients and recent pathogenetic and therapeutic advances. <i>Clinical and Experimental Medicine</i> , 2021, 21, 49-62.	1.9	11
22	Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral Centers. <i>Frontiers in Immunology</i> , 2021, 12, 627423.	2.2	25
23	Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2904-2906.e2.	2.0	56
24	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	3.1	19
25	Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma. <i>American Journal of Pathology</i> , 2021, 191, 748-758.	1.9	9
26	Spotlight on Cardiovascular Scoring Systems in Covid-19: Severity Correlations in Real-world Setting. <i>Current Problems in Cardiology</i> , 2021, 46, 100819.	1.1	9
27	Antibiotics or No Antibiotics, That Is the Question: An Update on Efficient and Effective Use of Antibiotics in Dental Practice. <i>Antibiotics</i> , 2021, 10, 550.	1.5	27
28	Uridine and pyruvate protect T cellsâ€™ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study. <i>Scientific Reports</i> , 2021, 11, 12841.	1.6	8
29	Galectin-3 and neutrophil-to-lymphocyte ratio are indicative of heart remodelling and disease severity in patients with obstructive sleep apnoea. <i>Sleep Medicine</i> , 2021, 82, 117-124.	0.8	8
30	COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. <i>Journal of Clinical Medicine</i> , 2021, 10, 2920.	1.0	57
31	Prognostic and Therapeutic Role of Angiogenic Microenvironment in Thyroid Cancer. <i>Cancers</i> , 2021, 13, 2775.	1.7	10
32	Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy. <i>Cancer Biology and Therapy</i> , 2021, 22, 404-412.	1.5	4
33	The Spectrum of Ocular Manifestations in Patients with WaldenstrÃ¶mâ€™s Macroglobulinemia. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-10.	1.0	5
34	MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. <i>Cancers</i> , 2021, 13, 3650.	1.7	13
35	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
36	Artificial Intelligence in Dermatopathology: New Insights and Perspectives. <i>Dermatopathology (Basel)</i> , 2021, 10, 10.	0.7	20

#	ARTICLE	IF	CITATIONS
37	Corona Virus Disease 19 (CoViD-19) impact on cardiovascular disease in a non-CoViD-19 emergency setting. <i>Internal and Emergency Medicine</i> , 2021, 16, 1377-1379.	1.0	4
38	Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression. <i>Cells</i> , 2021, 10, 3185.	1.8	16
39	Current Take on Systemic Sclerosis Patientsâ€™ Vaccination Recommendations. <i>Vaccines</i> , 2021, 9, 1426.	2.1	17
40	Omalizumab for the Treatment of Persistent Drug Induced Urticaria Elicited by Thienopyridines: A Case Report. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2020, 19, 335-339.	1.1	1
41	Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. <i>Clinical and Experimental Medicine</i> , 2020, 20, 11-19.	1.9	24
42	Amyloidosis and Ocular Involvement: an Overview. <i>Seminars in Ophthalmology</i> , 2020, 35, 7-26.	0.8	22
43	New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. <i>Cancers</i> , 2020, 12, 1869.	1.7	41
44	Actors on the Scene: Immune Cells in the Myeloma Niche. <i>Frontiers in Oncology</i> , 2020, 10, 599098.	1.3	51
45	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. <i>Cancers</i> , 2020, 12, 3380.	1.7	71
46	Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. <i>Mediators of Inflammation</i> , 2020, 2020, 1-25.	1.4	129
47	Telemedicine DSS-AI Multi Level Platform for Monoclonal Gammopathy Assistance. , 2020, , .		6
48	The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network;) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	2.0	15
49	Right Heart Changes Impact on Clinical Phenotype of Amyloid Cardiac Involvement: A Single Centre Study. <i>Life</i> , 2020, 10, 247.	1.1	7
50	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3054.	1.8	41
51	MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3084.	1.8	42
52	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1594.	1.0	49
53	Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1765.	1.0	22
54	Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 429-437.	1.5	59

#	ARTICLE	IF	CITATIONS
55	<p>Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements</p>. Clinical Ophthalmology, 2020, Volume 14, 775-793.	0.9	13
56	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 552.	1.0	40
57	Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 613.	1.8	35
58	Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells, 2020, 9, 167.	1.8	68
59	HB-EGF–EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers, 2020, 12, 173.	1.7	28
60	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real–Life Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
61	Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype. Frontiers in Immunology, 2020, 11, 319.	2.2	8
62	Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department. Frontiers in Medicine, 2020, 7, 625176.	1.2	21
63	A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche. Journal of Oncology, 2020, 2020, 1-16.	0.6	8
64	Long-Term Follow-Up May be Useful in Coronavirus Disease 2019 Survivors to Prevent Chronic Complications. Infection and Chemotherapy, 2020, 52, 407.	1.0	8
65	Hypersensitivity to Vitamins with a Focus on Immediate-Type Reactions: Food or Drug Allergy?. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 21, .	0.6	1
66	Promising Use of the New Biologics in the Management of Drug-Induced Hypersensitivity Reactions: Preliminary Approaches. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1456-1469.	0.6	1
67	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. Journal of Clinical Medicine, 2019, 8, 997.	1.0	45
68	Polyethylene glycols and polysorbates: Two still neglected ingredients causing true IgE-mediated reactions. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2509-2510.	2.0	25
69	Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. Cancers, 2019, 11, 1270.	1.7	25
70	Mast Cells and Angiogenesis in Human Plasma Cell Malignancies. International Journal of Molecular Sciences, 2019, 20, 481.	1.8	18
71	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. Journal of Hematology and Oncology, 2019, 12, 4.	6.9	27
72	Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. Cancers, 2019, 11, 321.	1.7	24

#	ARTICLE	IF	CITATIONS
73	Functional interplay between NF- κ B-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma. <i>Haematologica</i> , 2019, 104, 2465-2481.	1.7	5
74	Phthalimide Derivative Shows Anti-angiogenic Activity in a 3D Microfluidic Model and No Teratogenicity in Zebrafish Embryos. <i>Frontiers in Pharmacology</i> , 2019, 10, 349.	1.6	20
75	Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 349-358.	2.5	81
76	Idiopathic nonhistaminergic angioedema: A single-center real-life experience from Italy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1389-1392.	2.7	5
77	Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review). <i>Oncology Reports</i> , 2019, 41, 2615-2624.	1.2	18
78	Intelligent Microarray Data Analysis through Non-negative Matrix Factorization to Study Human Multiple Myeloma Cell Lines. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 5552.	1.3	9
79	Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs. <i>Journal of Clinical Medicine</i> , 2019, 8, 2030.	1.0	61
80	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma—Enhanced Angiogenesis: A Novel Therapeutic Target?. <i>Neoplasia</i> , 2019, 21, 93-105.	2.3	28
81	Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 59-76.	2.6	12
82	Should succinate esters be considered excipients in systemic corticosteroid allergy?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 342-343.	2.0	1
83	Cancer Stem Cells in Multiple Myeloma and the Development of Novel Therapeutic Strategies. , 2019, , 121-137.		2
84	Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. <i>Clinical and Experimental Medicine</i> , 2019, 19, 1-21.	1.9	39
85	Bone marrow endothelial cells sustain a tumor-specific CD8 ⁺ T cell subset with suppressive function in myeloma patients. <i>Oncolimmunology</i> , 2019, 8, e1486949.	2.1	58
86	Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. <i>Journal of Pathology</i> , 2019, 247, 241-253.	2.1	74
87	Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival. <i>Blood</i> , 2019, 134, 855-855.	0.6	7
88	The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. <i>Blood</i> , 2019, 134, 1899-1899.	0.6	2
89	Amicrobial pustulosis or erosive pustular dermatosis of the inguinal folds: broad of the same spectrum?. <i>Italian Journal of Dermatology and Venereology</i> , 2019, , .	0.1	0
90	Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 318-323.	0.5	21

#	ARTICLE	IF	CITATIONS
91	A favorable response to omalizumab in a patient with cheilitis granulomatosa. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1425-1426.	2.0	2
92	Efficacy and rapid activity of omalizumab retreatment in chronic spontaneous urticaria. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1211-1213.	0.6	6
93	JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. <i>Leukemia</i> , 2018, 32, 736-743.	3.3	55
94	The role of SIRT6 in tumors. <i>Haematologica</i> , 2018, 103, 1-4.	1.7	39
95	Different Adaptive Responses to Hypoxia in Normal and Multiple Myeloma Endothelial Cells. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 203-212.	1.1	34
96	Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 1251-1258.	0.8	13
97	Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. <i>Clinical Immunology</i> , 2018, 191, 110-115.	1.4	62
98	A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis. <i>Medicine (United States)</i> , 2018, 97, e12355.	0.4	10
99	Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.3	4
100	Injured skin as risk factor for chlorhexidine anaphylaxis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2177.	2.0	3
101	Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPIn [®] protein MP0250: a preclinical study. <i>Oncotarget</i> , 2018, 9, 13366-13381.	0.8	37
102	Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1926-1935.	0.8	14
103	Analysis of Aortic Remodeling and Stiffness in Patients with Obstructive Sleep Apnea Syndrome: Preliminary Results. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1072, 251-255.	0.8	4
104	Mucine-1 Is Related to Cell-Mediated Immunoexpression and Blood Pressure in Pulmonary Artery in Pulmonary Arterial Hypertension (PAH): Preliminary Results. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1072, 275-280.	0.8	1
105	Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma. <i>Translational Oncology</i> , 2018, 11, 1350-1357.	1.7	56
106	Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy. <i>Clinical Drug Investigation</i> , 2018, 38, 955-965.	1.1	3
107	Hemodynamic Stress, Inflammation, and Intracranial Aneurysm Development and Rupture: A Systematic Review. <i>World Neurosurgery</i> , 2018, 115, 234-244.	0.7	102
108	Improving knowledge on the activation of bone marrow fibroblasts in MGUS and MM disease through the automatic extraction of genes via a nonnegative matrix factorization approach on gene expression profiles. <i>Journal of Translational Medicine</i> , 2018, 16, 217.	1.8	14

#	ARTICLE	IF	CITATIONS
109	New Insights in Anti-Angiogenesis in Multiple Myeloma. International Journal of Molecular Sciences, 2018, 19, 2031.	1.8	54
110	Common Variable Immunodeficiency and Gastric Malignancies. International Journal of Molecular Sciences, 2018, 19, 451.	1.8	38
111	Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers. Ocular Immunology and Inflammation, 2018, 26, 1154-1165.	1.0	28
112	Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease. Blood, 2018, 132, 4455-4455.	0.6	3
113	Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. Oncotarget, 2018, 9, 20563-20577.	0.8	45
114	Correlations between severity of obstructive sleep apnoea and systolic pulmonary artery pressure: preliminary results. , 2018, , .		0
115	MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. Blood, 2018, 132, 1980-1980.	0.6	1
116	Cancer treatment and the KIRâ€“HLA system: an overview. Clinical and Experimental Medicine, 2017, 17, 419-429.	1.9	21
117	Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. Arthritis Research and Therapy, 2017, 19, 74.	1.6	44
118	Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies. International Journal of Immunopathology and Pharmacology, 2017, 30, 73-82.	1.0	21
119	The small subunit of Hemilipin2, a new heterodimeric phospholipase A2 from Hemiscorpius lepturus scorpion venom, mediates the antiangiogenic effect of the whole protein. Toxicon, 2017, 126, 38-46.	0.8	29
120	Anti-Angiogenesis in Multiple Myeloma. , 2017, , 39-50.		0
121	Management of common variable immunodeficiency by subcutaneous IgG selfâ€“administration during pregnancy â€“ a case report. Clinical Case Reports (discontinued), 2017, 5, 1309-1311.	0.2	4
122	Involvement of new oxidative stress markers in chronic spontaneous urticaria. Postepy Dermatologii I Alergologii, 2017, 5, 448-452.	0.4	15
123	HEAVY-CHAIN DISEASES AND MYELOMA-ASSOCIATED FANCONI SYNDROME: AN UPDATE. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018011.	0.5	10
124	Epha3 acts as proangiogenic factor in multiple myeloma. Oncotarget, 2017, 8, 34298-34309.	0.8	23
125	NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27. Oncotarget, 2017, 8, 35088-35102.	0.8	20
126	A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma. Current Medicinal Chemistry, 2017, 24, 2736-2744.	1.2	71

#	ARTICLE	IF	CITATIONS
127	Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies. <i>Stem Cells International</i> , 2016, 2016, 1-11.	1.2	25
128	Extramedullary Plasmacytoma Mimicking Pancreatic Cancer: An Unusual Presentation. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.2	2
129	Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma. <i>Oncotarget</i> , 2016, 7, 29677-29688.	0.8	13
130	Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. <i>Journal of Pathology</i> , 2016, 239, 162-173.	2.1	185
131	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	0.6	144
132	Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch. <i>Cancer Treatment and Research</i> , 2016, 169, 51-61.	0.2	14
133	A joint allergist/cardiologist classification for thienopyridines hypersensitivity reactions based on their symptomatic patterns and its impact on the management strategies. <i>International Journal of Cardiology</i> , 2016, 222, 509-514.	0.8	3
134	Targeting B-cell non Hodgkin lymphoma: New and old tricks. <i>Leukemia Research</i> , 2016, 42, 93-104.	0.4	51
135	Isolation and characterization of neural stem cells from dystrophic mdx mouse. <i>Experimental Cell Research</i> , 2016, 343, 190-207.	1.2	12
136	Targeting vasculogenesis to prevent progression in multiple myeloma. <i>Leukemia</i> , 2016, 30, 1103-1115.	3.3	46
137	Echocardiographic findings and plasma endothelin-1 levels in obese patients with and without obstructive sleep apnea. <i>Sleep and Breathing</i> , 2016, 20, 613-619.	0.9	13
138	Halting pro-survival autophagy by TGF β 2 inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. <i>Leukemia</i> , 2016, 30, 640-648.	3.3	69
139	JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 307-307.	0.6	1
140	Microenvironment drug resistance in multiple myeloma: emerging new players. <i>Oncotarget</i> , 2016, 7, 60698-60711.	0.8	137
141	Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients. <i>Oncotarget</i> , 2016, 7, 14510-14521.	0.8	17
142	Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?. <i>Current Medicinal Chemistry</i> , 2016, 23, 4286-4296.	1.2	8
143	Probiotics and refractory chronic spontaneous urticaria. <i>European Annals of Allergy and Clinical Immunology</i> , 2016, 48, 182-7.	0.4	11
144	Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. <i>Blood</i> , 2015, 126, 1443-1451.	0.6	78

#	ARTICLE	IF	CITATIONS
145	Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells <i>in vitro</i> . <i>European Journal of Haematology</i> , 2015, 95, 65-74.	1.1	17
146	Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 6018-6025.	1.4	42
147	Cancer associated fibroblasts in hematological malignancies. <i>Oncotarget</i> , 2015, 6, 2589-2603.	0.8	46
148	Jejunal overexpression of peptide YY in celiac disease complicated with pneumatosis cystoides intestinalis. <i>Clinical and Experimental Medicine</i> , 2015, 15, 527-532.	1.9	1
149	Fainting as an unusual presentation of a large inferior vena cava leiomyosarcoma. <i>Phlebology</i> , 2015, 30, 492-495.	0.6	1
150	Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 46-61.	2.0	64
151	Multiple Myeloma as a Model for the Role of Bone Marrow Niches in the Control of Angiogenesis. <i>International Review of Cell and Molecular Biology</i> , 2015, 314, 259-282.	1.6	30
152	Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. <i>Oncolmmunology</i> , 2015, 4, e1008850.	2.1	27
153	“Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”. <i>Leukemia Research</i> , 2015, 39, 279-283.	0.4	11
154	Is the localized seminal plasma hypersensitivity the mucosal aspect of protein contact dermatitis?. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1090-1091.	1.5	11
155	Hemilipin, a novel <i>Hemiscorpius lepturus</i> venom heterodimeric phospholipase A2, which inhibits angiogenesis <i>in vitro</i> and <i>in vivo</i> . <i>Toxicon</i> , 2015, 105, 34-44.	0.8	39
156	18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. <i>Clinical and Experimental Medicine</i> , 2015, 15, 1-18.	1.9	60
157	Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. <i>Clinical and Experimental Medicine</i> , 2015, 15, 145-150.	1.9	26
158	Identify multiple myeloma stem cells: Utopia?. <i>World Journal of Stem Cells</i> , 2015, 7, 84.	1.3	14
159	Relationship between echocardiographic assessment and plasma endothelin-1 levels in obese patients with or without obstructive sleep apnea. , 2015, , .		1
160	Angiogenesis in Multiple Myeloma. <i>Chemical Immunology and Allergy</i> , 2014, 99, 180-196.	1.7	50
161	Correlation between Serum Tryptase, Mast Cells Positive to Tryptase and Microvascular Density in Colo-Rectal Cancer Patients: Possible Biological-Clinical Significance. <i>PLoS ONE</i> , 2014, 9, e99512.	1.1	59
162	Bone marrow vascular niche and the control of angiogenesis in multiple myeloma. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 304.	3.0	15

#	ARTICLE	IF	CITATIONS
163	Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma. <i>Cancers</i> , 2014, 6, 1363-1381.	1.7	68
164	A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5796-5807.	3.2	56
165	Stimulation of invariant natural killer T cells by α -Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model. <i>British Journal of Haematology</i> , 2014, 167, 651-663.	1.2	12
166	HIF-1 α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 847-858.	3.2	54
167	Role of endothelial progenitor cells in cancer progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 26-39.	3.3	70
168	Dendritic cell maturation in HCV infection: Altered regulation of MHC class I antigen processing-presenting machinery. <i>Journal of Hepatology</i> , 2014, 61, 242-251.	1.8	14
169	Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. <i>Leukemia</i> , 2014, 28, 904-916.	3.3	88
170	Chronic inflammation enhances NGF- β /TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome. <i>Journal of Molecular Medicine</i> , 2014, 92, 523-37.	1.7	14
171	Macrophages in multiple myeloma. <i>Immunology Letters</i> , 2014, 161, 241-244.	1.1	28
172	Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme. <i>Cancer Letters</i> , 2014, 353, 41-51.	3.2	13
173	Bone marrow dendritic cells induce myeloma cell resistance to CD8+ T cell-mediated killing. <i>Journal of Biotechnology</i> , 2014, 185, S14.	1.9	0
174	Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2014, 4, 17.	1.2	25
175	Therapeutic targeting of the mTOR signaling pathway in cancer: benefits and limitations. <i>British Journal of Pharmacology</i> , 2014, 171, 3801-3813.	2.7	92
176	Microenvironment and multiple myeloma spread. <i>Thrombosis Research</i> , 2014, 133, S102-S106.	0.8	40
177	THU0061...Vitamin D Insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 197.2-197.	0.5	0
178	SAT0297...Non-Invasive Assessment of Silent Liver Fibrosis in Patients with Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 700.2-700.	0.5	0
179	AB0608...Elevated Circulating Tumor-Associated Antigens in Systemic Sclerosis: Association with Lung Fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1007.1-1007.	0.5	0
180	The Role of Inflammatory Cells in Angiogenesis in Multiple Myeloma. <i>Advances in Experimental Medicine and Biology</i> , 2014, 816, 361-376.	0.8	11

#	ARTICLE	IF	CITATIONS
181	Novel agents and new therapeutic approaches for treatment of multiple myeloma. World Journal of Methodology, 2014, 4, 73.	1.1	32
182	Molecular diagnosis and the Italian Board for ISAC. European Annals of Allergy and Clinical Immunology, 2014, 46, 68.	0.4	7
183	Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans. Blood, 2014, 124, 5678-5678.	0.6	0
184	Cancer Associated Fibroblasts in Multiple Myeloma: The Urokinase Receptor System in Tumor Growth Regulation. Blood, 2014, 124, 5687-5687.	0.6	0
185	Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. Clinical and Experimental Rheumatology, 2014, 32, 267-74.	0.4	18
186	Molecular diagnosis and the Italian Board for ISAC. European Annals of Allergy and Clinical Immunology, 2014, 46, 68-73.	0.4	9
187	Rupatadine for the treatment of urticaria. Expert Opinion on Pharmacotherapy, 2013, 14, 1807-1813.	0.9	13
188	The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1029-1033.	2.7	62
189	Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma. Angiogenesis, 2013, 16, 963-973.	3.7	21
190	The Role of Angiogenesis in Human Non-Hodgkin Lymphomas. Neoplasia, 2013, 15, 231-238.	2.3	70
191	Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clinical and Experimental Medicine, 2013, 13, 85-97.	1.9	63
192	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. Journal of Pathology, 2013, 229, 87-98.	2.1	34
193	Long-term selective IgE-mediated hypersensitivity to hydrocortisone sodium succinate. Allergologia Et Immunopathologia, 2013, 41, 206-208.	1.0	7
194	MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells. Journal of the National Cancer Institute, 2013, 105, 1172-1187.	3.0	457
195	B16-F10 melanoma cells contribute to the new formation of blood vessels in the chick embryo chorioallantoic membrane through vasculogenic mimicry. Clinical and Experimental Medicine, 2013, 13, 143-147.	1.9	12
196	Neutropenia and G-CSF in lymphoproliferative diseases. Hematology, 2013, 18, 131-137.	0.7	7
197	Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma. Clinical Cancer Research, 2013, 19, 4371-4382.	3.2	60
198	Evidence for Bone Marrow Adult Stem Cell Plasticity: Properties, Molecular Mechanisms, Negative Aspects, and Clinical Applications of Hematopoietic and Mesenchymal Stem Cells Transdifferentiation. Stem Cells International, 2013, 2013, 1-11.	1.2	37

#	ARTICLE	IF	CITATIONS
199	Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. <i>Tumori</i> , 2013, 99, e241-e244.	0.6	4
200	Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report. <i>Oncology Letters</i> , 2013, 5, 1877-1880.	0.8	4
201	Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: Possible predictive role of response to treatment. <i>Molecular and Clinical Oncology</i> , 2013, 1, 385-389.	0.4	19
202	Short-Term Tolerability of Morniflumate in Patients with Cutaneous Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 247-250.	1.0	7
203	Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment. <i>Journal of Oncology</i> , 2013, 2013, 1-6.	0.6	49
204	Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature. , 2013, , 241-254.		1
205	A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents. <i>International Journal of Clinical and Experimental Medicine</i> , 2013, 6, 30-8.	1.3	9
206	Inflammation and Antiangiogenesis in Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 955-960.	1.2	12
207	High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma. <i>Hematology</i> , 2012, 17, 23-27.	0.7	18
208	Diagnosis of Latex Allergy: The Importance of Hev b 11. <i>International Archives of Allergy and Immunology</i> , 2012, 159, 147-148.	0.9	1
209	Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma. <i>Stem Cells International</i> , 2012, 2012, 1-6.	1.2	10
210	Novel strategies in the treatment of castration-resistant prostate cancer (Review). <i>International Journal of Oncology</i> , 2012, 40, 1313-20.	1.4	19
211	Antiangiogenic Therapeutic Approaches in Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2012, 12, 768-775.	0.8	13
212	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012, 97, 416-422.	1.7	61
213	Retinoids: novel immunomodulators and tumour-suppressive agents?. <i>British Journal of Pharmacology</i> , 2012, 167, 483-492.	2.7	20
214	Latex immunotherapy: state of the art. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 160-165.	0.5	33
215	High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. <i>Clinical and Experimental Medicine</i> , 2012, 12, 165-171.	1.9	15
216	Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. <i>Oncogene</i> , 2012, 31, 2258-2269.	2.6	31

#	ARTICLE	IF	CITATIONS
217	Kounis Syndrome induced by intravenous administration of piperacillin/tazobactam: A case report. <i>International Journal of Cardiology</i> , 2012, 155, e42-e44.	0.8	12
218	Aquaporin-4 expression in primary human central nervous system lymphomas correlates with tumour cell proliferation and phenotypic heterogeneity of the vessel wall. <i>European Journal of Cancer</i> , 2012, 48, 772-781.	1.3	8
219	Tumor endothelial markers as a target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 1215-1225.	1.5	28
220	Immune Effects and Polychlorinated Biphenyls, Smoking and Alcohol. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 1041-1054.	1.0	9
221	Angiogenesis in unknown primary tumors. <i>Clinical and Experimental Medicine</i> , 2012, 12, 67-68.	1.9	0
222	Could Multiple Myeloma VEGF Modify the Systemic Microcirculation?. <i>Advances in Experimental Medicine and Biology</i> , 2012, 737, 155-160.	0.8	3
223	Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.. <i>Blood</i> , 2012, 120, 2926-2926.	0.6	0
224	Immediate-type hypersensitivity to systemic glucocorticoids: An underrated drug allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 251.	1.5	2
225	Antibody Vh Repertoire Differences between Resolving and Chronically Evolving Hepatitis C Virus Infections. <i>PLoS ONE</i> , 2011, 6, e25606.	1.1	31
226	Acquired Angioedema with C1 Inhibitor Deficiency Associated with Anticardiolipin Antibodies. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 1115-1118.	1.0	6
227	Dasatinib: An Anti-Tumour Agent via Src Inhibition. <i>Current Drug Targets</i> , 2011, 12, 563-578.	1.0	93
228	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. <i>Current Drug Metabolism</i> , 2011, 12, 918-931.	0.7	11
229	Extra-articular manifestations of rheumatoid arthritis: An update. <i>Autoimmunity Reviews</i> , 2011, 11, 123-131.	2.5	151
230	Orbital pseudotumor in a child: diagnostic implications and treatment strategies. <i>Clinical and Experimental Medicine</i> , 2011, 11, 61-63.	1.9	13
231	The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. <i>Clinical Biochemistry</i> , 2011, 44, 1005-1011.	0.8	91
232	Cyclosporin-A Efficacy in Chronic Idiopathic Urticaria. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 195-200.	1.0	19
233	⁹⁰ Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 891-895.	2.8	5
234	Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1935-1946.	3.2	75

#	ARTICLE	IF	CITATIONS
235	Endothelial progenitor cells in sudden sensorineural hearing loss. <i>Acta Oto-Laryngologica</i> , 2011, 131, 347-350.	0.3	20
236	Angiogenesis and Vasculogenesis in Multiple Myeloma: Role of Inflammatory Cells. <i>Recent Results in Cancer Research</i> , 2011, 183, 87-95.	1.8	25
237	Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor as a Target for Capecitabine: From Biology to the Bedside. , 2011, , 31-54.		0
238	Bortezomib in the Treatment of Cancer. , 2011, , 273-283.		1
239	Serum tryptase evaluation in HCC patients who underwent transarterial chemoembolization.. <i>Journal of Clinical Oncology</i> , 2011, 29, e13543-e13543.	0.8	0
240	Is Soybean Patch Testing a Valid Diagnostic Tool for Adult Atopic Dermatitis? A Comparison of Two Methods. <i>Dermatitis</i> , 2011, 22, 230-231.	0.8	0
241	Bone marrow angiogenesis and progression in multiple myeloma. <i>American Journal of Blood Research</i> , 2011, 1, 76-89.	0.6	35
242	Intussusceptive microvascular growth in human glioma. <i>Clinical and Experimental Medicine</i> , 2010, 10, 93-98.	1.9	55
243	Hypersensitivity to tranexamic acid: a wide spectrum of adverse reactions. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 416-419.	1.4	51
244	The Italian Society of Immunology: past, present and future. <i>European Journal of Immunology</i> , 2010, 40, 2664-2666.	1.6	1
245	Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. <i>Bone Marrow Transplantation</i> , 2010, 45, 277-281.	1.3	26
246	Immediate rhinoconjunctivitis induced by metamizole: an allergic reaction?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1070-1071.	2.7	3
247	Angiogenesis and Progression in Human Melanoma. <i>Dermatology Research and Practice</i> , 2010, 2010, 1-6.	0.3	31
248	The Employment of Leukotriene Antagonists in Cutaneous Diseases Belonging to Allergological Field. <i>Mediators of Inflammation</i> , 2010, 2010, 1-6.	1.4	15
249	Effect of Low-Density Lipoprotein Apheresis on Circulating Endothelial Progenitor Cells in Familial Hypercholesterolemia. <i>Blood Purification</i> , 2010, 29, 383-389.	0.9	17
250	Allergen Component Resolved Diagnostics in Multi-Sensitized Patients with Respiratory Symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, AB136.	1.5	1
251	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. <i>European Journal of Cancer</i> , 2010, 46, 420-429.	1.3	65
252	38 ANTIANGIOGENIC PROPERTIES OF IMMUNOMODULATORY DRUG LENALIDOMIDE IN ENDOTHELIAL CELLS OF PATIENTS WITH ACTIVE MULTIPLE MYELOMA. <i>Cancer Treatment Reviews</i> , 2010, 36, S106.	3.4	0

#	ARTICLE	IF	CITATIONS
253	The safety of a novel sublingual rush induction phase for latex desensitization. <i>Current Medical Research and Opinion</i> , 2010, 26, 1855-1859.	0.9	18
254	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. <i>Blood</i> , 2010, 116, 966-966.	0.6	3
255	The Role of Dental Series Patch Tests in Oral Mucosal Diseases. <i>Dermatitis</i> , 2010, 21, 123-124.	0.8	3
256	Managing myelodysplastic symptoms in elderly patients. <i>Clinical Interventions in Aging</i> , 2009, 4, 413.	1.3	40
257	Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?. <i>Advances in Hematology</i> , 2009, 2009, 1-6.	0.6	3
258	Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 5369-5378.	3.2	91
259	Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling. <i>European Respiratory Journal</i> , 2009, 34, 958-966.	3.1	13
260	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	1.1	21
261	Angiogenesis in asthma. <i>Clinical and Experimental Allergy</i> , 2009, 39, 1815-1821.	1.4	62
262	Maculopapular rash due to fluconazole. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 404-404.	0.6	8
263	Monoclonal gammopathy as a marker of primary cerebral lymphoma. <i>European Journal of Clinical Investigation</i> , 2009, 39, 627-629.	1.7	1
264	The role of monocytes-macrophages in vasculogenesis in multiple myeloma. <i>Leukemia</i> , 2009, 23, 1535-1536.	3.3	32
265	Tomato atopy patch test in adult atopic dermatitis: diagnostic value and comparison among different methods. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 659-663.	2.7	1
266	Treatment of acquired cold urticaria with rupatadine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1387-1388.	2.7	9
267	Tumoral mast cells exhibit a common spatial distribution. <i>Cancer Letters</i> , 2009, 273, 80-85.	3.2	18
268	An alternative in vivo system for testing angiogenic potential of human neuroblastoma cells. <i>Cancer Letters</i> , 2009, 277, 199-204.	3.2	19
269	Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S28-S29.	1.4	0
270	MicroRNAs to know in Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 4133-4134.	0.6	1

#	ARTICLE	IF	CITATIONS
271	Long-Term Tolerability of Etoricoxib in Patients with Previous Reactions to Non-Steroidal Anti-Inflammatory Drugs. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 1131-1134.	1.0	5
272	Angiogenesis and anti-angiogenesis in haematological diseases. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 31-33.	0.3	4
273	The role of microenvironment in tumor angiogenesis. <i>Genes and Nutrition</i> , 2008, 3, 29-34.	1.2	58
274	Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. <i>Clinical and Experimental Medicine</i> , 2008, 8, 141-145.	1.9	18
275	Contact allergy to benzocaine in a condom. <i>Contact Dermatitis</i> , 2008, 59, 173-174.	0.8	20
276	Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. <i>Oncogene</i> , 2008, 27, 663-674.	2.6	129
277	A case of Cogan's syndrome resolved with mycophenolate sodium. <i>European Journal of Clinical Investigation</i> , 2008, 38, 605-605.	1.7	3
278	Delayed complete remission in a patient with multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2008, 38, 966-968.	1.7	1
279	Angiogenic activity of multiple myeloma endothelial cells <i>in vivo</i> in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1023-1028.	1.6	24
280	Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. <i>Peptides</i> , 2008, 29, 1596-1602.	1.2	62
281	Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 100, 82-85.	0.5	12
282	Endothelial Differentiation of Hematopoietic Stem and Progenitor Cells from Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2008, 14, 1678-1685.	3.2	44
283	Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2008, 14, 1849-1858.	3.2	75
284	Mast Cells Contribute to Vasculogenic Mimicry in Multiple Myeloma. <i>Stem Cells and Development</i> , 2008, 17, 19-22.	1.1	65
285	Parecoxib as an Alternative in COX-2 Hypersensitivity. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 233-235.	1.0	5
286	Validation of PDGFR ^β and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. <i>Blood</i> , 2008, 112, 1346-1356.	0.6	99
287	Soluble Intercellular Adhesion Molecule 1 and Soluble Vascular Cell Adhesion Molecule 1 in Sudden Hearing Loss. <i>Otology and Neurotology</i> , 2008, 29, 470-474.	0.7	43
288	Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria. <i>Journal of Asthma and Allergy</i> , 2008, 2, 17.	1.5	10

#	ARTICLE	IF	CITATIONS
289	Clodronate inhibits angiogenesis in vitro and in vivo. <i>Oncology Reports</i> , 2008, 19, 1109-12.	1.2	24
290	Overview of Angiogenesis During Tumor Growth. , 2008, , 161-168.		6
291	Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 923-930.	0.6	9
292	Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3256-3262.	1.9	74
293	Evaluation of Tumor Necrosis Factor- α and Granulocyte Colony-Stimulating Factor Serum Levels in Lead-Exposed Smoker Workers. <i>International Journal of Immunopathology and Pharmacology</i> , 2007, 20, 239-247.	1.0	25
294	The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. <i>Cytokine and Growth Factor Reviews</i> , 2007, 18, 327-334.	3.2	78
295	The structure of the vascular network of tumors. <i>Cancer Letters</i> , 2007, 248, 18-23.	3.2	97
296	Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 1575-1578.	0.4	25
297	Bcr-Abl stabilizes β -catenin in chronic myeloid leukemia through its tyrosine phosphorylation. <i>EMBO Journal</i> , 2007, 26, 1456-1466.	3.5	204
298	The history of the angiogenic switch concept. <i>Leukemia</i> , 2007, 21, 44-52.	3.3	207
299	Morphometry and mathematical modelling of the capillary-like patterns formed in vitro by bone marrow macrophages of patients with multiple myeloma. <i>Leukemia</i> , 2007, 21, 2201-2203.	3.3	8
300	Imaging and angiogenesis in hematological malignancies. <i>Leukemia</i> , 2007, 21, 1605-1605.	3.3	3
301	Macrophages and tumor angiogenesis. <i>Leukemia</i> , 2007, 21, 2085-2089.	3.3	66
302	Delayed-type hypersensitivity to bupivacaine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1345-1346.	2.7	16
303	Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. <i>Histopathology</i> , 2007, 50, 636-641.	1.6	36
304	Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. <i>Histopathology</i> , 2007, 50, 591-596.	1.6	57
305	Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. <i>Histopathology</i> , 2007, 51, 837-842.	1.6	54
306	Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. <i>British Journal of Dermatology</i> , 2007, 156, 674-681.	1.4	65

#	ARTICLE	IF	CITATIONS
307	Mast cells in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 26, 1-4.	1.0	47
308	Neridronate inhibits angiogenesis in vitro and in vivo. <i>Clinical Rheumatology</i> , 2007, 26, 1094-1098.	1.0	33
309	Dasatinib Inhibits Multiple Myeloma Growth by Blocking PDGF-Rb and c-Src Activity in Patient-Derived Tumor and Endothelial Cells.. <i>Blood</i> , 2007, 110, 550-550.	0.6	2
310	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstromâ€™s Macroglobulinemia.. <i>Blood</i> , 2007, 110, 1383-1383.	0.6	2
311	Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia. <i>Haematologica</i> , 2007, 92, 1367-74.	1.7	11
312	In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. <i>Histology and Histopathology</i> , 2007, 22, 285-9.	0.5	19
313	Angiogenesis in Chronic Lymphocytic Leukemia: An Emerging Target. <i>Clinical Leukemia</i> , 2006, 1, 118-122.	0.2	4
314	Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: Correlation with the extent of angiogenesis and disease-progression risk in early disease. <i>Leukemia and Lymphoma</i> , 2006, 47, 1034-1040.	0.6	13
315	FLOW CYTOMETRIC BASOPHIL ACTIVATION TEST: DETECTION OF CD63 EXPRESSION AS A USEFUL AID TO DIAGNOSIS OF LATEX ALLERGY. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 715-716.	0.5	14
316	Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2006, 32, 437-444.	3.4	77
317	Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. <i>Blood</i> , 2006, 108, 1661-1667.	0.6	79
318	Thymidine Phosphorylase (Platelet-Derived Endothelial Cell Growth Factor) as a Target for Capecitabine: From Biology to the Bedside. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 171-183.	0.8	5
319	Bortezomib in the Treatment of Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 397-403.	0.8	66
320	Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. <i>British Journal of Dermatology</i> , 2006, 154, 533-538.	1.4	56
321	Desloratadine in combination with montelukast suppresses the dermatographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. <i>British Journal of Dermatology</i> , 2006, 155, 1279-1282.	1.4	43
322	The contribution of Bruce Glick to the definition of the role played by the bursa of Fabricius in the development of the B cell lineage. <i>Clinical and Experimental Immunology</i> , 2006, 145, 1-4.	1.1	32
323	The gelatin spongeâ€™chorioallantoic membrane assay. <i>Nature Protocols</i> , 2006, 1, 85-91.	5.5	229
324	Bone marrow angiogenesis in multiple myeloma. <i>Leukemia</i> , 2006, 20, 193-199.	3.3	175

#	ARTICLE	IF	CITATIONS
325	Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. <i>Oncogene</i> , 2006, 25, 4257-4266.	2.6	159
326	Miller's seminal studies on the role of thymus in immunity. <i>Clinical and Experimental Immunology</i> , 2006, 144, 371-375.	1.1	21
327	Acute Intrathoracic Gastric Volvulus from a Diaphragmatic Hernia after Left Splenopancreatectomy: Report of a Case. <i>Surgery Today</i> , 2006, 36, 981-984.	0.7	12
328	Stephen Paget and the "seed and soil"™ theory of metastatic dissemination. <i>Clinical and Experimental Medicine</i> , 2006, 6, 145-149.	1.9	180
329	Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. <i>European Journal of Haematology</i> , 2006, 76, 51-57.	1.1	10
330	Bortezomib as an Antitumor Agent. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 441-448.	0.9	75
331	Editorial [Hot Topic: Novel Agents for Multiple Myeloma Treatment (Guest Editors: D. Ribatti and A. Tj ETQq1 1 0.784314 rgBT /Overl	0.9	0
332	Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon- β . <i>British Journal of Cancer</i> , 2006, 94, 1845-1852.	2.9	42
333	Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. <i>Cancer Research</i> , 2006, 66, 184-191.	0.4	266
334	Angiogenesis in rheumatoid arthritis. <i>Histology and Histopathology</i> , 2006, 21, 557-66.	0.5	135
335	Intense Reversal of Bone Marrow Angiogenesis after Consolidation Therapy with Alemtuzumab in Advanced Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 4985-4985.	0.6	0
336	New aspects of myeloma management. <i>Blood</i> , 2005, 106, 395-395.	0.6	0
337	Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 1961-1965.	0.7	98
338	Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. <i>British Journal of Haematology</i> , 2005, 129, 248-256.	1.2	91
339	Acquired C1-inhibitor deficiency in a patient with systemic lupus erythematosus: a case report and review of the literature. <i>European Journal of Clinical Investigation</i> , 2005, 35, 781-784.	1.7	25
340	Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. <i>Leukemia</i> , 2005, 19, 1525-1531.	3.3	56
341	Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. <i>Oncogene</i> , 2005, 24, 6785-6795.	2.6	63
342	Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. <i>Journal of Cellular Physiology</i> , 2005, 205, 414-421.	2.0	69

#	ARTICLE	IF	CITATIONS
343	Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies. <i>Current Cancer Drug Targets</i> , 2005, 5, 573-578.	0.8	22
344	Antiangiogenesis by Chemotherapeutic Agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 313-317.	1.1	7
345	Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5334-5346.	0.8	125
346	Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 95, 438-442.	0.5	22
347	The role of adrenomedullin in angiogenesis. <i>Peptides</i> , 2005, 26, 1670-1675.	1.2	62
348	Endothelial progenitor cells in health and disease. <i>Histology and Histopathology</i> , 2005, 20, 1351-8.	0.5	22
349	Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy. <i>Haematologica</i> , 2005, 90, 698-700.	1.7	3
350	Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. <i>Oncology Reports</i> , 2005, 14, 81-4.	1.2	46
351	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1438-1445.	1.8	61
352	Hematopoietic Cancer and Angiogenesis. <i>Stem Cells and Development</i> , 2004, 13, 484-495.	1.1	38
353	Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. <i>The Hematology Journal</i> , 2004, 5, 118-122.	2.0	30
354	Mast cell contribution to angiogenesis related to tumour progression. <i>Clinical and Experimental Allergy</i> , 2004, 34, 1660-1664.	1.4	97
355	Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. <i>Journal of Anatomy</i> , 2004, 204, 433-449.	0.9	100
356	Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. <i>Leukemia</i> , 2004, 18, 331-336.	3.3	52
357	Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. <i>Leukemia</i> , 2004, 18, 1054-1058.	3.3	76
358	Order and disorder in the vascular network. <i>Leukemia</i> , 2004, 18, 1745-1750.	3.3	35
359	Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. <i>European Journal of Haematology</i> , 2004, 73, 36-42.	1.1	24
360	Vascular endothelial growth factor-A, vascular endothelial growth factor receptor-2 and angiopoietin-2 expression in the mouse choroid plexuses. <i>Brain Research</i> , 2004, 1013, 256-259.	1.1	15

#	ARTICLE	IF	CITATIONS
361	Angiogenesis in Neuroblastoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 133-142.	1.8	62
362	Angiogenesis in acute and chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2004, 28, 321-324.	0.4	33
363	Genetic and epigenetic mechanisms of multiple myeloma. <i>Drug Discovery Today Disease Mechanisms</i> , 2004, 1, 357-364.	0.8	1
364	CXCR3-binding chemokines in multiple myeloma. <i>Cancer Letters</i> , 2004, 207, 221-227.	3.2	50
365	Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy. <i>Cancer Letters</i> , 2004, 216, 103-107.	3.2	24
366	Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. <i>Peptides</i> , 2004, 25, 2179-2185.	1.2	69
367	A possible role of tryptase in angiogenesis in the brain of mdx mouse, a model of Duchenne muscular dystrophy. <i>Neuroscience</i> , 2004, 123, 585-588.	1.1	17
368	Setting the stage: an anatomist's view of the immune system. <i>Trends in Immunology</i> , 2004, 25, 210-217.	2.9	74
369	A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. <i>Microvascular Research</i> , 2004, 67, 117-124.	1.1	125
370	VEGF and Tumor Progression in Human Melanoma. , 2004, , 48-53.		1
371	On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2003, 82, 262-262.	0.8	1
372	Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2003, 70, 373-378.	1.1	44
373	Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2003, 71, 137-139.	1.1	40
374	Erythropoietin as an angiogenic factor in gastric carcinoma. <i>Histopathology</i> , 2003, 42, 246-250.	1.6	53
375	In vivo time-course of the angiogenic response induced by multiple myeloma plasma cells in the chick embryo chorioallantoic membrane. <i>Journal of Anatomy</i> , 2003, 203, 323-328.	0.9	26
376	Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. <i>European Journal of Clinical Investigation</i> , 2003, 33, 420-425.	1.7	206
377	Erythropoietin as an angiogenic factor. <i>European Journal of Clinical Investigation</i> , 2003, 33, 891-896.	1.7	135
378	Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2003, 17, 1428-1430.	3.3	71

#	ARTICLE	IF	CITATIONS
379	Vascular endothelial growth factor and its receptors in multiple myeloma. <i>Leukemia</i> , 2003, 17, 1961-1966.	3.3	74
380	Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. <i>Oncogene</i> , 2003, 22, 6458-6461.	2.6	56
381	Fenretinide as an anti-angiogenic agent in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 181-184.	3.2	20
382	Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. <i>European Journal of Cancer</i> , 2003, 39, 666-674.	1.3	122
383	New non-angiogenesis dependent pathways for tumour growth. <i>European Journal of Cancer</i> , 2003, 39, 1835-1841.	1.3	59
384	Thalidomide: a new anticancer drug?. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1211-1225.	1.9	34
385	Ultrastructural Analysis of Mast Cell Recovery after Secretion by Piecemeal Degranulation in B-cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 517-521.	0.6	21
386	Angiogenesis and Anti-Angiogenesis in Hematological Malignancies. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003, 12, 11-22.	1.8	27
387	Endothelial cells in the bone marrow of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3340-3348.	0.6	173
388	Cross Talk between Haematopoiesis and Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2003, 522, 25-36.	0.8	4
389	A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. <i>Haematologica</i> , 2003, 88, 176-85.	1.7	93
390	B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization. <i>Haematologica</i> , 2003, 88, 671-8.	1.7	27
391	In vivo activation of JAK2/STAT3 pathway during angiogenesis induced by GM-CSF. <i>FASEB Journal</i> , 2002, 16, 1-19.	0.2	126
392	Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 3344-3351.	0.6	120
393	IN SITU HYBRIDIZATION AND IMMUNOGOLD LOCALIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 ON THE PERICYTES OF THE CHICK CHORIOALLANTOIC MEMBRANE. <i>Cytokine</i> , 2002, 17, 262-265.	1.4	10
394	Endothelial Cell Heterogeneity and Organ Specificity. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 81-90.	1.8	137
395	Docetaxel Versus Paclitaxel for Antiangiogenesis. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 103-118.	1.8	119
396	Mast Cell Heterogeneity in B-cell Non-Hodgkin's Lymphomas: An Ultrastructural Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 2201-2205.	0.6	19

#	ARTICLE	IF	CITATIONS
397	Angiogenesis and anti-angiogenesis in neuroblastoma. <i>European Journal of Cancer</i> , 2002, 38, 750-757.	1.3	49
398	The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo. <i>European Journal of Cell Biology</i> , 2002, 81, 599-607.	1.6	44
399	Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 expression in mdx mouse brain. <i>Brain Research</i> , 2002, 953, 12-16.	1.1	23
400	In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. <i>International Journal of Cancer</i> , 2002, 102, 351-354.	2.3	52
401	Multiple myeloma and mycosis fungoides in the same patient: clinical, immunologic, and molecular studies. <i>Annals of Hematology</i> , 2002, 81, 326-331.	0.8	10
402	Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas. <i>European Journal of Clinical Investigation</i> , 2002, 32, 199-206.	1.7	53
403	Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. <i>Leukemia</i> , 2002, 16, 1680-1684.	3.3	73
404	Anti-angiogenic activity of the purine analog 6-thioguanine. <i>Leukemia</i> , 2002, 16, 1490-1499.	3.3	27
405	Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. <i>British Journal of Cancer</i> , 2002, 86, 993-998.	2.9	123
406	Cross-talk Between Hematopoiesis and Angiogenesis Signaling Pathways. <i>Current Molecular Medicine</i> , 2002, 2, 537-543.	0.6	32
407	Is thalidomide a true anti-angiogenic molecule in multiple myeloma?. <i>Haematologica</i> , 2002, 87, 344-5.	1.7	3
408	Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. <i>Haematologica</i> , 2002, 87, 836-45.	1.7	63
409	Postnatal vasculogenesis. <i>Mechanisms of Development</i> , 2001, 100, 157-163.	1.7	128
410	Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. <i>Life Sciences</i> , 2001, 68, 1161-1168.	2.0	58
411	Monocyte-macrophage system and polymorphonuclear leukocytes in workers exposed to low levels of metallic mercury. <i>Science of the Total Environment</i> , 2001, 270, 157-163.	3.9	32
412	Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. <i>British Journal of Haematology</i> , 2001, 113, 415-421.	1.2	97
413	The role of mast cells in tumour angiogenesis. <i>British Journal of Haematology</i> , 2001, 115, 514-521.	1.2	126
414	Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane. <i>Clinical and Experimental Allergy</i> , 2001, 31, 602-608.	1.4	71

#	ARTICLE	IF	CITATIONS
415	Inhibition of neuroblastoma-induced angiogenesis by fenretinide. <i>International Journal of Cancer</i> , 2001, 94, 314-321.	2.3	63
416	Chorioallantoic membrane capillary bed: A useful target for studying angiogenesis and anti-angiogenesis in vivo. <i>The Anatomical Record</i> , 2001, 264, 317-324.	2.3	235
417	Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 expression in the chick embryo area vasculosa. <i>The Histochemical Journal</i> , 2001, 33, 283-286.	0.6	10
418	Bone marrow angiogenesis in patients with active multiple myeloma. <i>Seminars in Oncology</i> , 2001, 28, 543-550.	0.8	77
419	α _v β ₃ integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. <i>Experimental Hematology</i> , 2001, 29, 993-1003.	0.2	76
420	Bone Marrow Angiogenesis and Plasma Cell Angiogenic and Invasive Potential in Patients with Active Multiple Myeloma. <i>Acta Haematologica</i> , 2001, 106, 162-169.	0.7	33
421	Role of Hematopoietic Growth Factors in Angiogenesis. <i>Acta Haematologica</i> , 2001, 106, 157-161.	0.7	10
422	Cell-Mediated Delivery of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor onto the Chick Chorioallantoic Membrane: Endothelial Fenestration and Angiogenesis. <i>Journal of Vascular Research</i> , 2001, 38, 389-397.	0.6	66
423	Angiogenic activity of leptin in the chick embryo chorioallantoic membrane is in part mediated by endogenous fibroblast growth factor-2. <i>International Journal of Molecular Medicine</i> , 2001, 8, 265-8.	1.8	39
424	Coordinate immunoreactivity to vascular endothelial growth factor receptor-2 and its ligand suggests a paracrine regulation during the development of the vascular system in the chick embryo bursa of Fabricius. <i>International Journal of Molecular Medicine</i> , 2001, 7, 365-8.	1.8	1
425	In Vivo Absence of Synergism Between Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 905-912.	1.8	12
426	Bone marrow angiogenesis in patients with active multiple myeloma. <i>Seminars in Oncology</i> , 2001, 28, 543-550.	0.8	58
427	Angiogenesis, angiogenic factor expression and hematological malignancies. <i>Anticancer Research</i> , 2001, 21, 4333-9.	0.5	15
428	The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis. <i>Current Pharmaceutical Biotechnology</i> , 2000, 1, 73-82.	0.9	106
429	Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. <i>International Journal of Cancer</i> , 2000, 85, 171-175.	2.3	82
430	TNP-470 and recombinant human interferon- γ 2a inhibit angiogenesis synergistically. <i>British Journal of Haematology</i> , 2000, 109, 829-837.	1.2	33
431	The discovery of angiogenic factors:. <i>General Pharmacology</i> , 2000, 35, 227-231.	0.7	92
432	An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis. <i>Inflammation Research</i> , 2000, 49, 418-423.	1.6	12

#	ARTICLE	IF	CITATIONS
433	Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. <i>International Journal of Cancer</i> , 2000, 85, 171-175.	2.3	128
434	Proteolytic Activity of Human Lymphoid Tumor Cells. Correlation with Tumor Progression. <i>Autoimmunity</i> , 2000, 7, 77-88.	0.6	24
435	State-of-the-Art Review: Hematopoiesis and Angiogenesis: A Link Between Two Apparently Independent Processes. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 13-19.	1.8	26
436	Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. <i>International Journal of Cancer</i> , 2000, 85, 171-5.	2.3	33
437	Models for Studying Angiogenesis in Vivo. <i>International Journal of Biological Markers</i> , 1999, 14, 207-213.	0.7	48
438	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. <i>Blood</i> , 1999, 93, 3064-3073.	0.6	537
439	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. <i>Blood</i> , 1999, 94, 4143-4155.	0.6	259
440	Angiogenesis in lipoma: An experimental study in the chick embryo chorioallantoic membrane.. <i>International Journal of Molecular Medicine</i> , 1999, 4, 593-6.	1.8	19
441	Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. <i>European Journal of Clinical Investigation</i> , 1999, 29, 793-801.	1.7	62
442	Temporal expression of the matrix metalloproteinase MMP-2 correlates with fibronectin immunoreactivity during the development of the vascular system in the chick embryo chorioallantoic membrane. <i>Journal of Anatomy</i> , 1999, 195, 39-44.	0.9	17
443	Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. <i>British Journal of Cancer</i> , 1999, 79, 965-970.	2.9	130
444	Endogenous and exogenous fibroblast growth factor-2 modulate wound healing in the chick embryo chorioallantoic membrane. <i>Angiogenesis</i> , 1999, 3, 89-95.	3.7	29
445	Localization of factor VIII-related antigen in the endothelium of the chick embryo chorioallantoic membrane. <i>Histochemistry and Cell Biology</i> , 1999, 112, 447-450.	0.8	14
446	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. , 1999, 189, 590-599.		35
447	The Role of the Vascular Phase in Solid Tumor Growth: A Historical Review. <i>Neoplasia</i> , 1999, 1, 293-302.	2.3	137
448	The trouble with vacuum extraction. <i>Current Obstetrics & Gynaecology</i> , 1999, 9, 41-45.	0.2	39
449	Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. <i>British Journal of Cancer</i> , 1999, 79, 451-455.	2.9	240
450	Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. , 1999, 189, 590.		3

#	ARTICLE	IF	CITATIONS
451	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>Blood</i> , 1999, 93, 2627-2636.	0.6	461
452	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>Blood</i> , 1999, 93, 2627-2636.	0.6	16
453	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. <i>Blood</i> , 1999, 93, 3064-3073.	0.6	119
454	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. <i>Blood</i> , 1999, 94, 4143-4155.	0.6	17
455	In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. <i>Journal of Cell Science</i> , 1999, 112, 4213-4221.	1.2	58
456	Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. <i>Blood</i> , 1999, 93, 2627-36.	0.6	145
457	Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. <i>Blood</i> , 1999, 93, 3064-73.	0.6	166
458	Antiangiogenesis is produced by nontoxic doses of vinblastine. <i>Blood</i> , 1999, 94, 4143-55.	0.6	85
459	TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. , 1998, 75, 246-253.		231
460	Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. , 1998, 77, 449-454.		54
461	Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. <i>Clinical Rheumatology</i> , 1998, 17, 115-120.	1.0	16
462	Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 55-68.	1.0	85
463	Expression of tenascin is related to angiogenesis in pre-eclampsia. <i>European Journal of Clinical Investigation</i> , 1998, 28, 373-378.	1.7	9
464	Lipoprotein (a) induces angiogenesis on the chick embryo chorioallantoic membrane. <i>European Journal of Clinical Investigation</i> , 1998, 28, 533-537.	1.7	13
465	Angiogenesis in hepatocellular carcinoma: an experimental study in the chick embryo chorioallantoic membrane.. <i>International Journal of Oncology</i> , 1998, 13, 17-21.	1.4	9
466	Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas?. <i>British Journal of Cancer</i> , 1998, 77, 1900-1906.	2.9	78
467	TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. , 1998, 75, 246.		1
468	Angiogenesis in Multiple Myeloma. , 1998, , 227-238.		0

#	ARTICLE	IF	CITATIONS
469	Role of basic fibroblast growth factor in the formation of the capillary plexus in the chick embryo chorioallantoic membrane. An in situ hybridization, immunohistochemical and ultrastructural study. <i>Journal of Submicroscopic Cytology and Pathology</i> , 1998, 30, 127-36.	0.3	14
470	Antiangiogenesis by cyclosporine. <i>Experimental Hematology</i> , 1998, 26, 1215-22.	0.2	39
471	Minimal immunological effects on workers with prolonged low exposure to inorganic mercury.. <i>Occupational and Environmental Medicine</i> , 1997, 54, 437-442.	1.3	40
472	Correlative study of angiogenesis in endometrial cancer assessed by the color Doppler ultrasound and by the chick embryo chorioallantoic membrane. <i>International Journal of Oncology</i> , 1997, 11, 1191-5.	1.4	2
473	New Model for the Study of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane: The Gelatin Sponge/ Chorioallantoic Membrane Assay. <i>Journal of Vascular Research</i> , 1997, 34, 455-463.	0.6	199
474	Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. <i>European Journal of Cancer</i> , 1997, 33, 1685-1692.	1.3	91
475	Exogenous heparin induces fibronectin overexpression parallel to angiogenesis in the extracellular matrix of the chick embryo chorioallantoic membrane. <i>Tissue and Cell</i> , 1997, 29, 131-136.	1.0	11
476	The Chick Embryo Chorioallantoic Membrane as an in vivo Wound Healing Model. <i>Pathology Research and Practice</i> , 1996, 192, 1068-1076.	1.0	31
477	Human Recombinant Interferon Alpha-2a Inhibits Angiogenesis of Chick Area Vasculosa in Shell-Less Culture. <i>International Journal of Microcirculation, Clinical and Experimental</i> , 1996, 16, 165-169.	0.6	19
478	Pyogenic Granuloma Stimulates Angiogenesis in the Chick Embryo Chorioallantoic Membrane. <i>International Journal of Microcirculation, Clinical and Experimental</i> , 1996, 16, 82-88.	0.6	8
479	Birth by vacuum extraction: Neonatal outcome. <i>Journal of Paediatrics and Child Health</i> , 1996, 32, 204-206.	0.4	19
480	Expression of Tenascin is Related to Histologic Malignancy and Angiogenesis in B-Cell non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 22, 473-481.	0.6	35
481	Determination of vascularization of B-cell non-Hodgkin's lymphomas with four markers. <i>International Journal of Oncology</i> , 1996, 8, 561-6.	1.4	0
482	Endometrial hyperplasia and endometrial carcinoma induce a vasoproliferative response in the chick embryo chorioallantoic membrane. <i>International Journal of Oncology</i> , 1996, 8, 1149-1153.	1.4	4
483	Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. <i>European Journal of Haematology</i> , 1996, 56, 45-53.	1.1	150
484	The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. <i>International Journal of Developmental Biology</i> , 1996, 40, 1189-97.	0.3	117
485	Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. <i>American Journal of Hematology</i> , 1995, 50, 9-14.	2.0	131
486	Expression of MAGE genes in primary and metastatic cutaneous melanoma. <i>International Journal of Cancer</i> , 1995, 63, 375-380.	2.3	261

#	ARTICLE	IF	CITATIONS
487	Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and \pm -interferon therapy. <i>International Journal of Clinical and Laboratory Research</i> , 1995, 25, 79-83.	1.0	9
488	Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. <i>Annals of Hematology</i> , 1995, 70, 313-318.	0.8	51
489	Angiogenesis in B Cell Lymphoproliferative Diseases. <i>Biological and Clinical Studies. Leukemia and Lymphoma</i> , 1995, 20, 27-38.	0.6	94
490	Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. <i>Annals of Hematology</i> , 1995, 70, 313-318.	0.8	3
491	Bone marrow angiogenesis and progression in multiple myeloma. <i>British Journal of Haematology</i> , 1994, 87, 503-508.	1.2	580
492	Differential expression of two ICAM-1 epitopes and LFA-1 chains in B-cell non-Hodgkin's lymphomas. <i>European Journal of Haematology</i> , 1994, 53, 85-92.	1.1	14
493	Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. <i>Cancer</i> , 1993, 72, 455-461.	2.0	99
494	Anti-angiogenesis: a multipurpose therapeutic tool?. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 117-120.	1.0	6
495	Deflazacort versus Prednisone in the Treatment of Essential Mixed Cryoglobulinemia A Between-Patient Controlled Clinical Study. <i>International Archives of Allergy and Immunology</i> , 1992, 99, 306-310.	0.9	13
496	Angiogenesis during tumor progression in human malignant melanoma. <i>Exs</i> , 1992, 61, 415-420.	1.4	23
497	A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. <i>Clinical and Experimental Immunology</i> , 1991, 84, 429-34.	1.1	30
498	Angiogenesis under normal and pathological conditions. <i>Haematologica</i> , 1991, 76, 311-20.	1.7	41
499	Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype. <i>Anticancer Research</i> , 1990, 10, 401-6.	0.5	31
500	Stimulatin of antibody response in the gastro-intestinal mucosa of immunodeficient mice by oral treatment with bacterial antigens. An immunoperoxidase study. <i>International Journal of Immunopharmacology</i> , 1989, 11, 341-348.	1.1	1
501	HBeAg/Anti-HBe circulating immune complexes in patients chronically infected with hepatitis B virus. <i>Research in Clinic and Laboratory</i> , 1989, 19, 81-91.	0.3	1
502	Imaging of human leukemic T-Cell Xenografts in nude mice by radiolabeled monoclonal antibodies and F(ab) ₂ fragments. <i>Cancer</i> , 1988, 61, 58-67.	2.0	14
503	Radioimmunotherapy of human colon carcinoma by ¹³¹ I-labelled monoclonal anti-cea antibodies in a nude mouse model. <i>International Journal of Cancer</i> , 1988, 41, 127-134.	2.3	66
504	Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. <i>Cancer Research</i> , 1987, 47, 1627-33.	0.4	110

#	ARTICLE	IF	CITATIONS
505	Expression on human thymocytes of the idiotypic structures (Ti) from two leukemia T cell lines Jurkat and HPB-ALL. European Journal of Immunology, 1986, 16, 649-652.	1.6	63
506	Monoclonal antibodies against idiotypic determinant(s) of the T cell receptor from HPB-ALL cells induce IL 2 production in Jurkat cells without apparent evidence of binding. European Journal of Immunology, 1986, 16, 823-828.	1.6	13
507	Treatment of multiple myeloma: A randomized study of three different regimens. Leukemia Research, 1985, 9, 1043-1049.	0.4	20
508	Angiogenesis and Antiangiogenesis in Multiple Myeloma. , 0, , .		1
509	Human Chorionic Gonadotropin Inhibits Kaposi's Sarcoma Associated Angiogenesis, Matrix Metalloprotease Activity, and Tumor Growth. , 0, .		8